Investigational drug · Phase 2
PEGPH20
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Pancreatic Adenocarcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 21, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
22
Any phase or sponsor naming "PEGPH20"
First trial start
2017
Jul 5, 2017
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PEGPH20", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pancreatic Adenocarcinoma
Approved drugs for the same conditions: Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "PEGPH20" as an intervention, largest first.
Halozyme TherapeuticsIndustry
NCT02715804 · 492 participants · Start Mar 14, 2016 · Primary completion Nov 4, 2019
Drug: Placebo; nab-Paclitaxel and 1 more · For: Pancreatic Ductal Carcinoma
Sites: Mobile, Alabama; Gilbert, Arizona; Fayetteville, Arkansas · 217 sites in all
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03193190 · 341 participants · Start Jul 5, 2017 · Primary completion Feb 27, 2025
Drug: Nab-Paclitaxel; Gemcitabine and 13 more · For: Pancreatic Adenocarcinoma
Sites: Duarte, California; San Francisco, California; New Haven, Connecticut · 23 sites in all
- PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic CancerPivotal-lookingCompleted
Halozyme TherapeuticsIndustry
NCT01839487 · 279 participants · Start May 14, 2013 · Primary completion May 1, 2018
Drug: PEGPH20; Nab-paclitaxel and 3 more · For: Metastatic Pancreatic Cancer
Sites: Birmingham, Alabama; Mobile, Alabama; Gilbert, Arizona · 51 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03281369 · 219 participants · Start Oct 13, 2017 · Primary completion Oct 9, 2025
Drug: 5-Fluorouracil (5-FU); Leucovorin and 13 more · For: Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
Sites: Scottsdale, Arizona; Los Angeles, California; Santa Monica, California · 28 sites in all
- S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic CancerPivotal-lookingCompleted
SWOG Cancer Research NetworkResearch network
NCT01959139 · 126 participants · Start Jan 23, 2014 · Primary completion Apr 2019
Drug: PEGPH20; Oxaliplatin and 3 more · For: Metastatic Pancreatic Adenocarcinoma
Sites: Anchorage, Alaska; Tucson, Arizona; Auburn, California · 154 sites in all
- Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic AdenocarcinomaActive, not recruiting
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT02921022 · 110 participants (planned) · Start Oct 2016 · Primary completion Oct 2027
Drug: Gemcitabine; Nab-paclitaxel and 1 more · For: Pancreatic Cancer; Advanced Pancreatic Ductal Adenocarcinoma
Sites: Hartford, Connecticut; Miami, Florida; Basking Ridge, New Jersey · 10 sites in all
Halozyme TherapeuticsIndustry
NCT03267940 · 85 participants · Start Oct 2, 2017 · Primary completion Nov 11, 2019
Drug: PEGPH20; CIS and 2 more · For: Cholangiocarcinoma Non-resectable; Cholangiocarcinoma, Intrahepatic; Cholangiocarcinoma, Extrahepatic and 1 more
Sites: Phoenix, Arizona; Tucson, Arizona; Duarte, California · 36 sites in all
Halozyme TherapeuticsIndustry
NCT02563548 · 56 participants · Start Oct 22, 2015 · Primary completion Mar 26, 2019
Drug: PEGPH20; Pembrolizumab · For: NSCLC; Gastric Cancer
Sites: Birmingham, Alabama; Scottsdale, Arizona; Encinitas, California · 28 sites in all
Pancreatic Cancer Research TeamAcademic, hospital or other
NCT03634332 · 35 participants (planned) · Start May 1, 2019 · Primary completion Oct 2020
Drug: PEGPH20; Pembrolizumab · For: Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer; Pancreatic Neoplasms
Sites: Gilbert, Arizona; Los Angeles, California; New Brunswick, New Jersey · 5 sites in all
Halozyme TherapeuticsIndustry
NCT01453153 · 28 participants · Start Sep 2011 · Primary completion Feb 2014
Drug: Gemcitabine; PEGPH20 and 1 more · For: Stage IV Pancreatic Cancer
Sites: Fayetteville, Arkansas; San Francisco, California; Indianapolis, Indiana · 12 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Emerging Therapeutic Strategies for Targeting Hyaluronan in Metabolic Disease from Molecular Design to Clinical Translation.
Feng M, Hu X, Zhou H · Int J Mol Sci 2026
- Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001.
Chiorean EG, Damle SR, Zhen DB, et al. · Cancers (Basel) 2026
- Hyaluronic acid and its role in pancreatic cancer: Mechanisms of tumor progression, drug resistance, and therapeutic targeting.
Cai W, Chen Y, Dai S, et al. · Pharmacol Res 2025
- Pancreatic Neuroendocrine Tumors Secrete Apolipoprotein E to Induce Tip Endothelial Cells That Remodel the Tumor-Stroma Ratio and Promote Cancer Progression.
Lou X, Shi Y, Zhao F, et al. · Cancer Res 2025
- Investigational Use of Real-World Data as a Hybrid Control in Pancreatic Ductal Adenocarcinoma From the Randomized Phase Ib/II MORPHEUS Trial.
Ko AH, Oh DY, Lau J, et al. · Clin Pharmacol Ther 2025
- siRNA-Encapsulated Biomimetic Liposomes Effectively Inhibit Tumor Cells' Hexosamine Biosynthesis Pathway for Attenuating Hyaluronan Barriers to Pancreatic Cancer Chemotherapy.
Wu J, Cheng Y, Qian K, et al. · ACS Nano 2025
Also in development for Pancreatic Adenocarcinoma
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
- GEMPhase 35 trials
Shenzhen Majory Biotechnology Co., Ltd. · Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Cancer, Recurrent or Metastatic Cervical Cancer
- AtebimetinibIMM-1-104, Group APhase 34 trials
Immuneering Corporation · Pancreatic Adenocarcinoma, Advanced Solid Tumor, Malignant Melanoma (Cutaneous)
- zoldonrasibPhase 34 trials
Revolution Medicines, Inc. · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC
- BL-8040Phase 32 trials
BioLineRx, Ltd. · Multiple Myeloma, Pancreatic Adenocarcinoma
- CF102NamodenosonPhase 32 trials
Can-Fite BioPharma · Pancreatic Adenocarcinoma, Pancreatic Cancer, Hepatocellular Carcinoma
- AB928Etrumadenant, ETRUMAPhase 24 trials
Arcus Biosciences, Inc. · Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
- ImzokitugBMS-986340Phase 22 trials
Bristol Myers Squibb · Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC), Cervical Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.